Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19791962 | 0.98 | TRPA1 (0.32) | TRPA1CYP3A4NLRP3ALDH1A1GABRA1 | |
| SCHEMBL20681025 | 0.98 | TRPA1 (0.32) | TRPA1CYP3A4NLRP3ALDH1A1GABRA1 | |
| SCHEMBL20692402 | 0.89 | GABRA1 (0.34) | TRPA1CYP3A4ALDH1A1GABRA1GABRB2 | |
| SCHEMBL25198843 | 0.85 | — | — | |
| SCHEMBL18007703 | 0.84 | NLRP3 (0.31) | NLRP3 | |
| SCHEMBL30041596 | 0.84 | — | — | |
| SCHEMBL25198839 | 0.84 | — | — | |
| SCHEMBL25196622 | 0.84 | — | — | |
| SCHEMBL21626260 | 0.84 | — | — | |
| SCHEMBL18007721 | 0.83 | MEN1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | GENENTECH, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12599616-B2 | Subtituted sulfonylurea and sulfoximineurea derivatives | ZYDUS LIFESCIENCES LIMITED (IN) | 2026-04-14 | — | — | US | disclosed |
| US-20250388568-A1 | NLRP3 INHIBITORS | KODIAK SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12466800-B2 | N-((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)-4, 5, 6, 7-tetrahydrobenzofuran-2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (MS) | ZOMAGEN BIOSCIENCES LTD (US) | 2025-11-11 | — | — | US | disclosed |
| US-12459925-B2 | Sulphonyl urea derivatives as NLRP3 inflammasome modulators | NodThera Limited (GB) | 2025-11-04 | — | — | US | disclosed |
| US-12377070-B2 | Substituted sulfoximine derivatives | ZYDUS LIFESCIENCES LIMITED (IN) | 2025-08-05 | — | — | US | disclosed |
| US-20250223263-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NodThera Limited (GB) | 2025-07-10 | — | — | US | disclosed |
| US-12351564-B2 | NLRP3 modulators | ZOMAGEN BIOSCIENCES LTD (US) | 2025-07-08 | — | — | US | disclosed |
| EP-3728238-B1 | SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS | NODTHERA LTD (GB) | 2025-06-18 | — | — | EP | disclosed |
| CN-113474333-B | Novel substituted sulphones ureide derivatives | 载度思生命科学有限公司 | 2025-06-13 | — | — | CN | disclosed |
| EP-1270565-B1 | 4-Substituted furan-2-sulfonamide and its use in the preparation of sulfonyl urea derivatives | PFIZER (US) | 2004-06-30 | — | — | EP | disclosed |
| EP-0964849-B1 | SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY | PFIZER (US) | 2003-06-04 | — | — | EP | disclosed |
| EP-1270554-A1 | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity | PFIZER INC. (US) | 2003-01-02 | — | — | EP | disclosed |
| EP-1270565-A1 | 4-Substituted furan-2-sulfonamide and its use in the preparation of sulfonyl urea derivatives | PFIZER INC. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6433009-B1 | TREATMENT OF AUTOIMMUNE, CARDIOVASCULAR, NERVOUS SYSTEM, GASTROINTESTINAL, RESPIRATORY SYSTEM, AND VIRAL DISORDERS; ANTIDIABETIC, ANTIARTHRITIC, ANTIINFLAMMATORY AND ANTIDEPRESSANT AGENTS | PFIZER INC | 2002-08-13 | — | — | US | disclosed |
| EP-1214087-A1 | COMBINATION TREATMENT WITH IL-1RA AND COMPOUNDS THAT INHIBIT IL-1 PROCESSING AND RELEASE | Pfizer Products Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001019390-A1 | COMBINATION TREATMENT WITH IL-1RA AND DIARYL SULPHONYL UREA COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2001-03-22 | — | — | WO | disclosed |
| US-6166064-A | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity | PFIZER INC (US) | 2000-12-26 | — | — | US | disclosed |
| EP-0964849-A1 | SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY | PFIZER INC. (US) | 1999-12-22 | — | — | EP | disclosed |
| WO-1998032733-A1 | SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY | PFIZER INC. (US) | 1998-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223263-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, NOD1, NLRP1 | TRPA1 853/4885CYP3A4 2832/4885NLRP3 1/4885 |
| US-12351564-B2 | NLRP3 modulators | NLRP3, NLRP1, NOD1 | TRPA1 85/4885CYP3A4 802/4885NLRP3 1/4885 |
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | NLRP3, NLRP1, PYCARD | TRPA1 53/4885CYP3A4 1480/4885NLRP3 1/4885 |
| US-12377070-B2 | Substituted sulfoximine derivatives | IL18, NLRP3, NOD1 | TRPA1 652/4885CYP3A4 1605/4885NLRP3 2/4885 |
| US-20250388568-A1 | NLRP3 INHIBITORS | NLRP3, NOD1, NLRP1 | TRPA1 71/4885CYP3A4 1437/4885NLRP3 1/4885 |
| US-12466800-B2 | N-((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)-4, 5, 6, 7-tetrahydrobenzofuran-2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (MS) | FFAR3, NLRP3, NOD1 | TRPA1 458/4885CYP3A4 659/4885NLRP3 2/4885 |
| US-12599616-B2 | Subtituted sulfonylurea and sulfoximineurea derivatives | NOD1, NLRP3, NOD2 | TRPA1 13/4885CYP3A4 1261/4885NLRP3 2/4885 |
| US-12459925-B2 | Sulphonyl urea derivatives as NLRP3 inflammasome modulators | NLRP3, NOD1, IL1B | TRPA1 594/4885CYP3A4 3263/4885NLRP3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.